Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Twenty of 33 committee members vote to keep rosiglitazone on the market, with most favoring stronger labeling and restrictions on prescribing.

Related Content

FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
Actos' Bladder Cancer Signal May Hinge On Dose, Duration Of Use
GSK Gets Chance For Input Into EU's Avandia Deliberations
Sentinel Initiative's Potential Shortcomings Illuminated At Avandia Panel
FDA Cites Meta-Analysis To Validate Surrogate Endpoint for Pfizer's Revatio
Avandia's EU Judgment Day Postponed, But GSK Gets Some Good News From CHMP
FDA Halts The TIDE Of New Avandia Patients; Informed Consent Changes Loom
Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010
Avandia's TIDE May Come In Smaller
Avandia Day Two Might Be Same Old Song Even With Broken RECORD





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts